BDX vs CTKB
BDX: A global medical technology leader providing essential healthcare supplies, diagnostic systems, and biosciences research tools to improve patient outcomes. CTKB: Cytek Biosciences provides advanced full-spectrum flow cytometry and single-cell analysis tools that enable researchers to perform high-resolution, multi-dimensional phenotyping.
Side-by-side fundamentals
| Metric | BDX | CTKB | Edge |
|---|---|---|---|
| Price as of 2026-10-21 close | $194.34 | $5.50 | |
| Market cap | $52.9B | $715M | |
| P/E as of 2026-10-21 | 58.71 | n/a | |
| Net margin FY2025, SEC XBRL | +7.7% | -33.0% | BDX higher |
| Gross margin FY2025, SEC XBRL | n/a | +51.8% | |
| Operating margin FY2025, SEC XBRL | +11.8% | -20.0% | BDX higher |
| ROE FY2025, SEC XBRL | +6.6% | -19.5% | BDX higher |
| ROA FY2025, SEC XBRL | +3.0% | -14.4% | BDX higher |
| Debt / equity filed borrowings, leases excl., balance sheet 2026-06-30 | 0.69 | n/a | |
| Revenue growth (YoY) FY2025, SEC XBRL | +8.2% | +0.5% | BDX higher |
| Revenue CAGR (3y) SEC XBRL | +5.0% | +7.1% | CTKB higher |
| Dividend yield as of 2026-09-03 | +2.3% | n/a | |
| Dividend streak (yrs) SEC XBRL | 13 | 0 | BDX higher |
| Beta as of 2026-09-03 | 0.45 | 1.21 | |
| 1-year return as of 2026-10-21 close | +30.8% | +31.9% | CTKB higher |
Fundamentals: SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-03 for the rest. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-10-21.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.